From the Department of Clinical and Movement Neuroscience (R.N.R., A.E.S.), UCL Queen Square Institute of Neurology, University College London; Centre for Preventive Neurology (A.J.N.) and Wolfson Institute of Population Health (A.J.N.), Queen Mary University of London; and Department of Neurology (R.N.R.), St George's University NHS Foundation Trust, London, UK.
Neurology. 2024 Jun 11;102(11):e209394. doi: 10.1212/WNL.0000000000209394. Epub 2024 May 17.
Parkinson disease (PD) remains a progressive and incurable disease. Research over the past decade provides strong evidence of a detectible phase before the clinical diagnosis, known as the prodromal phase of PD (pPD). In this article, we review the debate about disclosure of risk of progression to PD and related disorders to individuals through the perspectives of the pillars of medical ethics: beneficence, nonmaleficence, autonomy, and justice. There is evidence that lifestyle modification may have positive effects on onset and progression of PD, providing justification of potential benefit. From a societal perspective, a diagnosis of pPD could allow targeted recruitment to disease-modifying trials. Regarding nonmaleficence, direct evidence that catastrophic reactions are scarce is largely derived from studies of monogenic conditions, which may not be generalizable. Diagnosis of PD can be traumatic, and appropriate communication and evaluation of circumstances to weigh up disclosure is crucial. Future research should therefore examine the potential harms of early and of false-positive diagnoses and specifically examine these matters in diverse populations. Autonomy balances the right to know and the right not to know, so an individualized patient-centered approach and shared decision-making is essential, acknowledging that knowledge of being in the prodromal phase could prolong autonomy in the longer term. Distributive justice brings focus toward health care and related planning at the individual and societal level and affects the search for disease modification in PD. We must acknowledge that waiting for established disease states is likely to be and results in failures of expensive trials and wasted participant and researcher effort. Ultimately, clinicians must arrive at a decision with the patient that solicits and integrates patients' goals, taking into account their individual life circumstances, perspectives, and philosophies, recognizing that one size cannot fit all.
帕金森病(PD)仍然是一种进行性且无法治愈的疾病。过去十年的研究为在临床诊断之前存在可检测的阶段提供了有力证据,该阶段被称为 PD 的前驱期(pPD)。在本文中,我们从医学伦理的四大支柱(即有益、无害、自主和公正)的角度回顾了关于向个体披露进展为 PD 和相关疾病的风险的争论。有证据表明,生活方式的改变可能对 PD 的发病和进展产生积极影响,从而为潜在的益处提供了依据。从社会角度来看,pPD 的诊断可以允许针对疾病修饰试验进行有针对性的招募。关于无害原则,灾难性反应罕见的直接证据主要源自单基因疾病的研究,而这些研究结果可能不具有普遍性。PD 的诊断可能会带来创伤,因此,正确的沟通和对情况的评估以权衡披露的必要性至关重要。未来的研究因此应该研究早期和假阳性诊断的潜在危害,并在不同人群中具体研究这些问题。自主权平衡了知情权和拒绝权,因此,个体化的以患者为中心的方法和共同决策至关重要,同时也需要承认处于前驱期可能会在更长期内延长自主权。分配公正将注意力集中在个人和社会层面的医疗保健和相关规划上,并影响 PD 中的疾病修饰的探索。我们必须认识到,等待既定的疾病状态很可能会导致昂贵的试验失败,浪费参与者和研究人员的精力。最终,临床医生必须与患者共同做出决策,该决策要征求并整合患者的目标,同时考虑到他们的个人生活情况、观点和哲学,认识到不能一刀切。